<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083694</url>
  </required_header>
  <id_info>
    <org_study_id>UARK 98-032</org_study_id>
    <nct_id>NCT00083694</nct_id>
  </id_info>
  <brief_title>Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia</brief_title>
  <official_title>UARK, 98-032, Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients
      with leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will take Thalidomide tablets at bedtime daily until remission. The dose will be
      increased gradually and modified according to side-effects. The drug will be given daily up
      to the time of complete remission then as long as it is beneficial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1998</start_date>
  <completion_date>May 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy and safety of Thalidomide in patients with leukemia.</measure>
  </primary_outcome>
  <enrollment>25</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of refractory or relapsed leukemia: acute leukemia, CML, CLLm and MDS.

          -  Signed informed consent, including patient agreeing to use safe contraceptive methods
             during the treatment and for at least 4 months after the treatment is completed

          -  Serum creatinine &lt; or = 2.5mg/dL

          -  Serum bilirubin&lt; or = 2.5mg/dL

          -  Negative pregnancy test

          -  Age 18 years or older

          -  Performance status &lt; or = 3

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Concurrent treatment with cytotoxic chemotherapy, or radiation

          -  History of seizures, neurotoxicity, or active CNS disease

          -  Serious infections not controlled by antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barthel Barlogie, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences/MIRT</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://myeloma.uams.edu</url>
    <description>Myeloma Institute for Research &amp; Therapy website</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2004</study_first_submitted>
  <study_first_submitted_qc>May 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2004</study_first_posted>
  <last_update_submitted>July 1, 2010</last_update_submitted>
  <last_update_submitted_qc>July 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2010</last_update_posted>
  <keyword>Leukemia</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>relapsed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

